Philip Morris USA Inc.

Altria Client Services LLC

Philip Morris Products S.a.

Justin Heynekamp

Munmaya K Mishra

Gerd Kobal

Peter Reeh

Jason W Flora

Timothy B Langston

Tatjana Kichko

Tetyana Kichko

An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco.

Inhibition of sensory irritation during consumption of non-smokeable tobacco products

An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco. Also disclosed is a method of making such a product.

Pharmaceutical compositions and methods of use therefor for reducing the desire to engage in smoking are disclosed. More specifically, the pharmaceutical composition utilizes an active ingredient to reduce the side effects of smoking cessation and to limit the molecular feedback caused by nicotine-mediated activation of acetylcholine receptors.

Inhibition of central nervous system effects from smoking and sensory effects from smoking

Growing community of inventors

Glen Allen, VA, United States of America

Justin Heynekamp